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Summary: Patients with rheumatoid arthritis have decreased numbers of CR1 per erythrocyte and decreased
binding of immune complexes to erythrocytes. Overall erythrocyte immune complex binding activity depends
on both the number and the binding kinetics of CR13). We measured kinetic parameters for the interaction
between a complement-containing dsDNA: anti-dsDNA probe and erythrocytes in patients with rheumatoid
arthritis and normal controls. The results indicate that:
1) the maximum quantity of immune complexes bound per erythrocyte was significantly decreased in
rheumatoid arthritis compared with normal controls (p < 0.009);
2) the steady state binding constant, Kss, and the association rate constant for binding of immune complexes
to erythrocytes, ka, were significantly increased in rheumatoid arthritis versus normal controls (p < 0.0001
and 0.002 respectively);
3) the dissociation rate constant for the release of bound immune complexes from erythrocytes, kd, was
slightly smaller in rheumatoid arthritis but this difference was not statistically significant; and
4) the energies of activation for the association and dissociation reactions, Eaa, and Ead, did not differ between
the two groups.
These data confirm that while the maximum quantity of immune complexes bound per erythrocyte is decreased
in rheumatoid arthritis, the association rate constants are larger and dissociation rate constants slightly smaller
than those of normal controls. Changes in these kinetic parameters compensate for the decrease in the
maximum quantity of immune complexes bound per erythrocyte. A comparison of the product of Kss and
the maximum quantity of immune complexes bound per erythrocyte revealed no differences in the two groups,
indicating that at steady state overall CR1 binding activity is the same. The similar energies of activation
imply that the reaction mechanisms for the rate limiting steps of association and dissociation are similar and
cannot account for the observed increase in ka. These data suggest that the increased ka results from changes
in steric factors, such as the cross sectional area of the CR1 binding site. A model consistent with these
observations is presented.
!) This research was supported by the Minnesota Chapter of CR1, erythrocyte receptor for C3b component of comple-
the Arthritis Foundation. ment;
2) Presented in part at the American Rheumatism Association Eaa, energy of activation for association;
Meeting, Houston, Texas, June 1988. Ead, energy of activation for dissociation;
3) Abbreviations used in this paper: ka, association rate constant;
B, amount of DNA:antiDNA:C immune complex per eryth- kd, dissociation rate constant;
rocyte K,*, steady state constant;
S, amount of immune complexes bound per erythrocyte.
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Introduction
The erythrocyte receptor for the C3b component of
complement (CR1) is a single chain glycoprotein
found on the surface of peripheral blood cells, which
is capable of binding complement-containing immune
complexes. CR1 also acts as a cofactor for factor I-
dependent degradation of bound C3b prior to release
of immune complexes from the cell surface (1—4).
The integral role of these receptors in both immune
complex binding and the cleavage of complement
products, their abundant numbers in the circulation,
and the association of decreased receptor number with
active immune complex disease (5 — 7) suggest an im-
portant function for this receptor system in regulating
the concentration and character of immune complexes
in the circulation. Studies using monoclonal anti-CRl
antibodies have shown that the erythrocytes of pa-
tients with rheumatoid arthritis have fewer CR1 re-
ceptors than normal controls (8). Taylor et al. have
also demonstrated decreased binding of complement-
containing dsDNA: anti-dsDNA immune complexes
to erythrocytes in rheumatoid arthritis, compared
with erythrocytes from normal controls (9). Whether
this decreased binding was due to low levels of recep-
tors, abnormal CR1 binding function, or a combi-
nation of these factors was not determined.
The interaction between immune complexes and
erythrocyte CR1 involves binding via complement
fragments (primarily C3b), complement cleavage and
subsequent immune complex release. Due to the con-
secutive nature of these reactions and the altered size
of immune complexes after release (1, 10, 11), the
interaction of immune complexes with erythrocytes
cannot be considered a simple receptor-ligand inter-
action that reaches equilibrium. These consecutive
reactions will, however, reach a steady state when the
rate of immune complex binding to erythrocytes
equals the rate of their release. At steady state max-
imal binding will occur and there will be no change
in the overall concentration of bound immune com-
plexes over time.
The ratio of erythrocyte-bound to unbound immune
complexes at steady state is a function of both the
rate of association and the rate of dissociation. The
rate of association or dissociation is determined by
the appropriate rate constant and the concentration
of reacting species. Association and dissociation rate
constants, ka and kd, are independent of reactive spe-
cies concentrations, but depend upon the energy re-
quired for the rate limiting step (energy of activation,
Ea) and steric requirements of the respective reactions.
Alterations in rate constants secondary to changes in
Ea or steric conditions and/or concentrations of re-
acting species would change the ratio of erythrocyte-
bound to unbound immune complexes in the circu-
lation.
The overall immune complex binding activity of the
erythrocyte is regulated by both the binding capacity
and the binding function. Erythrocyte binding capac-
ity, defined as the maximum quantity of immune
complex which can bind per erythrocyte, is dependent
on the number of CR1 per erythrocyte. CR1 binding
function is defined by the rate parameters ka, kd, and
Kss. The experiments described here were designed to
compare immune complex binding capacity per eryth-
rocyte, rate constants of association and dissociation,
ka and kd, and the steady state constant, Kss, for
interactions of complement-containing DNA: anti-
DNA (DNA: anti-DNA: C) immune complexes with
erythrocytes from rheumatoid arthritis patients and
normal controls. Rate constants were also evaluated
at various temperatures, in order to determine ener-
gies of activation for the association and dissociation
reactions. Using these techniques, we previously dem-
onstrated that erythrocytes from systemic lupus ery-
thematosus patients had decreased immune complex
binding capacity, but normal CR1 immune complex
binding kinetics (12). In this study we demonstrate
that erythrocytes from rheumatoid arthritis patients
also have decreased binding capacity, but in addition,
have abnormal CR1 immune complex binding kinet-
ics.
Methods and Materials
Popula t ion studied
Erythrocytes were obtained from 18 patients with rheumatoid
arthritis and 15 normal controls. All patients met American
Rheumatoid Association (ARA) criteria for the diagnosis of
rheumatoid arthritis (13) and were followed in the outpatient
clinic at this institution. Nine patients were receiving prednisone
therapy with a mean dose of 8.6 mg/day, five patients were on
non-steroidal agents alone, and the remaining patients were on
combination therapy including non-steroidal agents, predni-
sone, and/or remittive agents.
Ery th rocy te suspensions
Peripheral blood was collected from normal controls and rheu-
matoid arthritis patients in standard EDTA tubes. Two ml of
blood were washed twice in gelatin-veronal buffer containing
EDTA, four times using gelatin-veronal buffer containing cal-
cium and magnesium (14), and diluted to a 20% suspension
with gelatin-veronal buffer containing calcium and magnesium.
Stock solutions of both buffer solutions were prepared, adjusted
to a pH of 7.3 using 1 mol/1 HC1, and diluted 1: 5 with deionized
water prior to use.
Prepara t ion of DNA : an t i -DNA : C immune com-
plexes
[3H]DNA (925 MBq/1 = 25 mCi/1) containing > 96% dsDNA
was obtained from New England Nuclear, Boston, MA. Plasma
containing high titer anti-dsDNA antibodies as quantitated by
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ELISA (15, 16) was obtained from one systemic lupus erythe-
matosus patient and used for all experiments. Anti-ssDNA
antibodies were also present in the plasma, but rheumatoid
factor, cryoglobulins, and antibodies directed against acidic
nuclear antigens were not detected. Following heat-inactivation
at 56 °C for 30 min, the systemic lupus erythematosus plasma
was centrifuged to remove any aggregated materials, aliquoted,
and stored at —20 °C until used. Lyophilized guinea pig serum
was obtained from ICN Immunobiologicals (Lisle, IL), recon-
stituted and diluted 1 :4 in gelatin-veronal buffer containing
calcium and magnesium prior to use.
Immune complexes containing [3H]dsDNA, anti-dsDNA anti-
bodies, and complement were prepared using a modification of
the procedure described by Taylor et al. (9). Aliquots of
[3H]dsDNA and plasma containing anti-dsDNA antibodies
were diluted in gelatin-veronal buffer containing calcium and
magnesium and incubated at 37 CC for 60 min. Diluted guinea
pig sera was added to the [3H]DNA: anti-DNA solution and
incubation continued for 30 min at 37 °C. Preliminary experi-
ments demonstrated that both immune complex formation and
activation of complement by these immune complexes reached
equilibrium within these incubation times.
Steady state exper iments
The steady state constant, K^, and the maximum amount of
DNA: anti-DNA: C bound per erythrocyte, were determined
by constructing a matrix consisting of varying concentrations
of erythrocytes and DNA: anti-DNA : C. Specifically, [3H]DNA
(30 μΐ) and anti-DNA (60 μΐ of plasma) were added to 5.9 ml
of gelatin-veronal buffer containing calcium and magnesium,
mixed, and incubated for 60 min at 37 °C. A 4.0 ml aliquot of
the DNA: anti-DNA solution was added to 500 μΐ of guinea
pig complement (diluted 1 :4 in gelatin-veronal buffer contain-
ing calcium and magnesium) and 1.5 ml of gelatin-veronal
buffer containing calcium and magnesium, and incubation con-
tinued for 30 min at 37 °C. This DNA: anti-DNA: C solution
was designated "neat" and serial dilutions of 1 :2, 1:4, and
1 :8 in gelatin-veronal buffer containing calcium and magne-
sium were prepared. A 20% erythrocyte suspension was diluted
in gelatin-veronal buffer containing calcium and magnesium to
yield 10, 5, 2.5, and 1.25% erythrocyte suspensions.
A four (DNA: anti-DNA: C dilutions) by five (erythrocyte
dilutions) matrix was constructed by mixing 100 μί of each
DNA: anti-DNA: C dilution and 100 μΐ of each erythrocyte
suspension, producing a total of 20 solutions with unique im-
mune complex to erythrocyte ratios. Negative control solutions
contained [3H]DNA: anti-DNA and erythrocytes only. The ma-
trix and control solutions were incubated at 37 °C for 30 min,
centrifuged, and a 100 μΐ aliquot of each supernatant removed
for quantitation of radioactivity. Since bound and unbound
radioactivity correlated closely in preliminary experiments, only
unbound [3H]DNA: anti-DNA: C radioactivity (supernatant)
was determined. To compare the effect of temperature on both
KSS and the maximum amount of immune complex bound to
erythrocytes, identical matrices were prepared and incubated
at 6, 15, 22, and 30 °C until maximal binding was achieved.
The length of incubation was extended at cooler temperatures
as determined from the plateau of binding noted in preliminary
rate experiments at each temperature.
Rate exper iments
The association rate constant, ka, for the binding of immune
complexes to erythrocytes, the dissociation rate constant, kd,
for the release of erythrocyte-bound immune complexes, and
the energies of activation for the association, Eaa, and dissocia-
tion, Ead, reactions were determined in the following way.
[3H]DNA (35 μί) and anti-DNA (70 μΐ of plasma) were added
to 6.9 ml of gelatin-veronal buffer containing calcium and
magnesium in a polystyrene tube. The solution was mixed and
incubated for 60 min at 37 °C. Guinea pig complement diluted
1 :4 in gelatin-veronal buffer containing calcium and magne-
sium (875 μί) and 2.6 ml of gelatin-veronal buffer containing
calcium and magnesium were then added to the DNA: anti-
DNA solution, mixed, and incubated for 30 min at 37 °C.
Equivalent amounts of this neat DNA: anti-DNA: C solution
and 20% erythrocyte suspension, both at 37 °C, were rapidly
mixed and sixteen timed aliquots (200 μί) removed from the
reaction mixture over a total of 60 —90 min. The aliquots were
immediately placed on ice to prevent further reaction, centri-
fuged at 4 CC, and 100 μΐ aliquots of the supernatants removed
for quantitation of radioactivity.
To determine the effect of temperature on ka and kd, and to
determine Eaa and Ead, the above procedure was repeated at 6,
15, 22, and 30 °C for each normal control and rheumatoid
arthritis patient studied. The timing of sample removal was
adjusted to account for slower reaction times at cooler temper-
atures.
Ca lcu la t ions
The consecutive interaction of immune complexes (1C) and
erythrocytes (RBC) is given by equation 1:
ka
RBC CR1 + 1C ^± RBC · 1C _Λ RBC CR1 + 1C* (eq. 1)
where 1C* represents modified immune complexes which pos-
sess little or no affinity for erythrocyte CR1. The constants ka
and kd' govern the rate of association and its reverse reaction
respectively, while kd governs factor I-mediated immune con-
plex dissociation. The values of kd determined in these experi-
ments include both kd and kd', but the reaction governed by
kd7 has been shown to be much slower than the dissociation
reaction governed by kd (17). Since this reaction contributes
minimally to the total concentration of unbound immune com-
plexes, the kd determined in this study reflects primarily factor
I-mediated C3b degradation and immune complex dissociation,
and calculations were simplified by not determining a specific
value for kd'.
Equations (2) and (3) give the relationships between rates of
association and dissociation, the respective rate constants ka
and kd, and concentrations of reactive species. In these equa-
tions, [RBC] and [1C] represent concentrations of erythrocytes
and immune complexes. The maximum amount of DNA: anti-
DNA : C which can bind per erythrocyte is represented by S,
while Β represents the amount of DNA: anti-DNA: C actually
bound per erythrocyte at a given time.
rate of association =
-d[IC]/dt = ka (S[RBC] - B[RBC]) ([1C]) (eq. 2)
rate of dissociation =
-d[RBC - IC]/dt = kdB[RBC] (eq. 3)
At steady state, the rates of association and dissociation are
equal and equations (2) and (3) may be combined to give the
steady state constant, Kss or the ratio of ka to kd:
— ka/kd —
Β
(S - B) ([1C])






Double reciprocal plots of 1/B (i.e., 1/bound 1C per erythro-
cyte) versus 1/[IC] (i. e., 1/unbound 1C) were linear over a broad
J. Clin. Chem. Clin. Biochem. / Vol. 28, 1990 / No. 8
536 Hargrove et al.: Altered CR1 binding kinetics in rheumatoid arthritis
range of immune complex and erythrocyte concentrations.
Slopes and intercepts of these plots represented l/iK^XS) and
1/S, respectively.
Rate constants for association were calculated using the initial
slopes of solution phase radioactivity (counts/mm) versus time
plots for the descending portion (binding) of each plot. Since
the concentration of immune complexes [1C] is directly related
to the radioactivity of the DNA: anti-DNA: C probe in solu-
tion, substitution of the initial slope, the initial radioactivity of
the solution (cpm°), and the concentration of erythrocytes into
equation (2), followed by rearrangement, yields equation (6).
Values of kaS were calculated from equation (6).
2000
initial slope/[RBC]cpm° = kaS (eq. 6)
Since K^S and kaS were determined from double reciprocal
plots (equation 5) and rate experiments (equation 6) respec-
tively, kd was calculated from the following relationship:
ss S = kaS/kd (eq. 7)
Energies of activation were evaluated from the Arrhenius equa-
tion (8):
ln(k) = ln(A) - Ea/RT (eq. 8)
where A is the frequency factor, R is the universal gas constant,
T is absolute temperature (Kelvin) and Ea is the energy of
activation. Plots of ln(kaS) and ln(kd) versus 1/T were linear
with slopes equal to Eaa/R and Ead/R, respectively.
Statistical analysis of data
All statistical correlations were obtained using the Pearson
product-moment coefficient (RS/1 Statistical Package, BBN
Research Systems, Cambridge, MA). Statistical comparisons
were made using Student's t-test.
Results
Bindingof immune complexes to erythrocytes
The interaction of [3H]DNA: anti-DNA: C complexes
with erythrocytes as a function of time is shown in
figure 1. The binding curve is characterized by an
initial decline in radioactivity corresponding to net
binding of immune complexes to erythrocytes (reach-
ing a maximum in the first ten minutes), a plateau
phase (extending up to 50 minutes), and a gradual
increase in radioactivity reflecting net immune com-
plex release from erythrocytes mediated by erythro-
cyte CR1 and factor I. Factor I, present in the donor
plasma and lyophilized guinea pig sera (dilutions of
1:300 and 1:25 respectively) used in preparing the
immune complex probe, was constant in all experi-
ments and allowed the binding, complement inacti-
vation, and release reactions to occur consecutively,
so that steady state parameters could be evaluated
and compared. Additional experiments performed in
the presence of incremental doses of purified factor I
showed that the initial binding of immune complexes
was not altered, while release of immune complexes
into the supernatant occurred more rapidly, as noted






Fig. 1. a) Binding of [3H]DNA: anti-DNA: C complexes to
erythrocytes as a function of time in representative
normal control (φ) and rheumatoid arthritis patient
(n).
b) Initial change in radioactivity determined from slope
of fitted polynomial for points in initial 30 minutes.
Steady state measurements made at 30—40 minutes.
Graphs show change in radioactivity of unbound im-
mune complex with time for normal control (A) and
rheumatoid arthritis patients (a).
The general shape of the association and dissociation
curves for the interaction of DNA: anti-DNA: C and
erythrocytes at 37 °C was similar in the 18 rheumatoid
arthritis patients and 15 normal controls examined.
Curves obtained from experiments performed at de-
creasing temperatures (30, 22, 15, and 6 °C) depicted
a progressive prolongation of binding and dissocia-
tion at each successively lower temperature.
Steady state binding studies
The Kss and the maximum amount of DNA:anti-
DNA : C bound per erythrocyte, S, were determined
by measuring concentrations of erythrocyte-bound
and unbound immune complexes at the time of max-
imal binding. A representative double reciprocal plot
illustrating data analysis from these experiments is
shown in figure 2. According to equation (5), the
slope and intercept of these plots are equivalent to 1 /
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10000
1/unbound DNA [counts/ min ]~
20000
Fig. 2. Double reciprocal plot (equation 5) of steady state con-
centrations of unbound versus erythrocyte-bound
[3H]DNA : anti-DNA: C complexes in a representative
rheumatoid arthritis patient.
(KSSS) and 1/S, respectively. Values of Kss and S de-
termined at five different temperatures are listed in
table 1. At all five temperatures the maximum amount
of DNA: anti-DNA: C bound per erythrocyte was
significantly decreased (p < 0.009), and Kss was sig-
nificantly increased (p < 0.0001) in rheumatoid ar-
thritis. To examine the overall effect of a simultaneous
increase in Kss and a decrease in S, the product Kss · S
for the two groups was compared (tab. 1). Despite
significantly larger mean Kss values in rheumatoid
arthritis, the Kss · S product was not statistically dif-
ferent from normal controls. These data suggest that
the increased Kss compensates for a decreased immune
complex binding capacity of erythrocytes in rheu-
matoid arthritis.
Rate studies
Rate studies were performed at five temperatures and
the rate constants of association, ka, and dissociation,
kd, were determined. The results of these studies, given
in table 2, show that the mean rate constant of as-
sociation, ka, is significantly larger in rheumatoid
arthritis patients than in normal controls (p < 0.025)
at all temperatures. Values of ka increased with in-
creasing temperature in both rheumatoid arthritis pa-
tients and controls, but the ratio of the mean ka in
rheumatoid arthritis patients to the mean ka in normal
controls remained constant. Values for kd were de-
creased in rheumatoid arthritis patients compared
with controls, but the decrease was not statistically
significant. A temperature-dependent increase in kd
was again noted in both groups, but the ratio of the
mean values remained constant.
Tab. 1. Mean values of steady state parameters for association/dissociation of DNA : anti-DNA : C complexes with erythrocytes
from rheumatoid arthritis patients and normal controls as a function of temperature
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Tab. 2. Rate constants of association and dissociation for the interaction of DNA: anti-DNA: C complexes with rheumatoid
arthritis and normal control erythrocytes as a function of temperature
Temperature, °C




















































































































Rate studies performed at different temperatures also
permitted calculation of the energies of activation for
both the association and dissociation reactions. The
energy of activation reflects the rate of change in rate
constants with temperature and provides an estimate





3.2 3.3 3Λ 3.5 3.6
κ-1]
Fig. 3. Arrhenius plots of temperature (Kelvin)-dependent
changes in rate constants in representative normal con-
trol (φ) and rheumatoid arthritis patient (D). Energies
of activation (Eaa, Ead) were determined from slopes of
fitted lines.
lecular bonds during the rate limiting step of the
reaction. Evaluation of this parameter allows a com-
parison of the molecular mechanisms for the rate
determining reactions in the two groups. Individual
plots of ln(ka · S) and ln(kd) versus 1/T were linear for
both rheumatoid arthritis patients and normal con-
trols (fig. 3). Table 3 lists mean values for Eaa and Ead
in rheumatoid arthritis patients and controls. The
identical energy values observed suggest that the
mechanism of the rate determining steps for immune
complex binding and release is similar in the two
Tab. 3. Mean energies of activation for association (Eaa) and
dissociation (Ead) of DNA: anti-DNA: C interaction
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groups. The normal Eaa values for rheumatoid ar-
thritis patients also suggest that the increase in ka was
not the result of a different reaction pathway. In
addition, the magnitude of the Eaa and Ead values
(approximately 40 kJ/mol) are comparable to the
energy involved in forming or breaking a hydrogen
bond (25 — 60 kJ/mol), suggesting that the rate deter-
mining steps of immune complex binding and disso-
ciation may involve formation or dissolution of a
hydrogen bond.
Discussion
We have demonstrated that in addition to reduced
immune complex binding to erythrocyte CR1 in rheu-
matoid arthritis there are also abnormalities in the
kinetic parameters regulating the interaction of
DNA: anti-DNA: C complexes with these receptors.
Overall binding characteristics of this receptor system
are determined by both binding function, as reflected
by ka, kd, and Kss, and the maximum quantity of
immune complex bound per erythrocyte, i.e. S, which
is a relative measure of the number of functional
binding sites. The rate constant of association, ka, was
significantly larger in rheumatoid arthritis patients
than in normal controls at all temperatures, while the
rate constant of dissociation, kd, although decreased
in rheumatoid arthritis, was not statistically different
from that of the controls. The steady state constant,
Kss (the ratio ka/kd), was significantly larger in rheu-
matoid arthritis patients. To further investigate the
aetiology of the increase in ka, we obtained the energy
of activation for the association reaction from Ar-
rhenius plots of rate data at various temperatures and
found no differences in these values for rheumatoid
arthritis patients and normal controls. These data
suggest that the increase in ka observed in rheumatoid
arthritis is due to more favourable steric conditions
during the interaction of the immune complex probe
with erythrocytes.
The maximum amount of immune complexes bound
per erythrocyte, S, is related to both the number of
CR1 binding sites available and the size of the probe
used. The composition and size of immune complexes
have been shown to affect their interaction with eryth-
rocyte CR1 (18- 20). The DNA: anti-DNA: C probe
used in these studies was large, containing multiple
C3b molecules. Binding of such a macromolecule may
require interaction with several clustered CR1 mole-
cules which together act as the functional CR1 bind-
ing site, while binding of smaller probes such as mono-
clonal antibodies may involve individual CR1 mole-
cules. Indeed, Paccaudzi al. used immunofluorescence
and electron microscopy to show that CR1 are clus-
tered on the surface of normal erythrocytes and the
cluster distribution is unchanged by immune complex
binding (21). Their values for the number of CR1 per
cell determined with monoclonal antibody (175 — 920)
and the number of clusters per cell as determined by
electron microscopy (range 7 to 82 clusters per eryth-
rocyte) correlated strongly, although the absolute val-
ues were quite different. Thus, the similar values of S
(as a relative measure of the number of functional
CR1 sites per cell) obtained in our experiments and
the number of clusters per cell as determined by
Paccaud et al. suggest that our DNA: anti-DNA: C
probe evaluated CR1 clusters rather than individual
CR1 molecules.
Although the results of these studies reveal abnor-
malities of both CR1 cluster number and kinetic pa-
rameters, the observed increase in ka would be ex-
pected to enhance immune complex binding, while
decreases in cluster number would contribute to de-
creased immune complex binding. Since the rate of
immune complex binding is a function of ka · S (equa-
tion 2), the overall effect of these two opposing factors
can be estimated by comparing ka · S in rheumatoid
arthritis and normal controls. The mean ka · S is sig-
nificantly lower in rheumatoid arthritis than in con-
trols (p < 0.02), indicating that the increase in ka only
partially compensates for lower receptor binding ca-
pacity, S.
The dissociation rate constant in rheumatoid arthritis
was lower than the control values, although the dif-
ference was not statistically significant. Nonetheless,
even a small decrease in kd contributes to the increased
value of Kss in rheumatoid arthritis, since Kss is de-
fined by the ratio of ka/kd. An increase in this ratio
leads to a larger ratio of erythrocyte-bound to free
immune complex. To assess the overall effect of the
changes in ka, kd, and S, we compared the ratio of
the rate of association to the rate of dissociation in
rheumatoid arthritis and normal controls. This ratio,
expressed by the product of Kss · S, was not different
in the two groups. The overall binding activity of
erythrocyte CR1 at steady state, therefore, as meas-
ured by both binding capacity and binding function,
is normal in rheumatoid arthritis. This normal binding
activity is due to an increase in ka and decrease in kd
which compensate for the decreased binding capacity,
S. Interestingly, this contrasts with results of similar
studies performed in our laboratory in systemic lupus
erythematosus patients, who also had decreased bind-
ing capacity, S, but normal Kss, ka, and kd values. The
compensatory changes in ka and kd seen in rheumatoid
arthritis may play a role in modulating immune com-
plex-mediated disease manifestations. The relative
failure of ka and kd to change in a similar fashion
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may contribute to the abnormal handling of immune
complexes in systemic lupus erythematosus.
To further examine factors contributing to the in-
creased ka observed in rheumatoid arthritis, rate ex-
periments were performed at different temperatures.
The Arrhenius equation (equation 8) defines the rate
constant for a reaction in terms of an energy factor
(energy of activation, Ea) and a steric factor (the
frequency factor, A). The increase in ka seen in rheu-
matoid arthritis must result from either an increase
in the frequency factor or a decrease in the energy of
activation. The frequency factor is related to steric
conditions including the cross sectional area of react-
ing molecules and the reduced mass of colliding mol-
ecules. Since the mean value of Eaa was normal in
rheumatoid arthritis this parameter does not account
for the increase in ka. Consequently, the larger ka
value must result from an increase in the frequency
factor, A. Finally, the changes in ka and A in rheu-
matoid arthritis may be accounted for by an increase
in the cross-sectional area of the functional CR1 bind-
ing site.
In the context of the work of Paccaud et al. showing
that immune complexes bind to a cluster of CR1
molecules on the erythrocyte surface, a model con-
sistent with our data suggests that erythrocytes from
rheumatoid arthritis patients have fewer binding clus-
ters per cell than normal controls, but more CR1
molecules in each binding cluster. Individual CR1
molecules within these binding clusters are structur-
ally identical. The model accounts for the decreased
binding of large probes, such as DNA: anti-DNA: C,
by a decrease in the number of binding clusters. Sim-
ilarly, the larger ka can be accounted for by an in-
creased number of CR1 molecules per cluster. More
CR1 molecules per binding cluster would increase the
cross-sectional area of the binding site thereby in-
creasing the value of the frequency factor and leading
to an increase in ka as observed in our experiments.
Finally, a normal Eaa would be expected if the indi-
vidual CR1 molecules in rheumatoid arthritis and
normal controls were structurally identical, so that
the rate limiting step of binding would be unaffected.
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